- Email: [email protected]
4970070 Protective monoclonal antibody compositions for infections due to group B streptococcus
122
PATENT ABSTRACTS
4966999 RADIOHALOGENATED COMPOUNDS FOR SITE SPECIFIC LABELING Daniel J Coughlin, Benjamin A Belinka, Vernon Alvarez assigned to Cytogen Corporation Radiohalogenated compounds which are useful as intermediates for preparing radiohalogenated antibody conjugates in which the radiohalogenated compound is site specifically attached to an oxidized carbohydrate moiety of an antibody or antibody fragment are disclosed. Methods for making the compounds and the antibody conjugates as well as methods of use of the same are also disclosed In particular, phenolic hydrazide and phenolic amine compounds are disclosed.
The presence of multiple gene copies in tumor cells indicates that the disease is more likely to spread beyond the primary tumor site, and that the disease therefore may require more aggressive treatment than might otherwise be indicated by other diagnostic factors. In particular, the degree of gene amplification appears to provide greater prognostic utility than either the estrogen receptor or the progesterone receptor, and provides utility equal to that of the determination of lymph node status. The information provided by the gene amplification test, however, is not duplicative with the determination of lymph node status and the two tests together provide greatly improved prognostic utility.
4968616 SUPEROXIDE DISMUTASE DERIVATIVES, METHOD OF PRODUCING SAME AND MEDICINAL USE OF SAME
4968493 METHOD FOR CONTROLLING CHRONIC RESPIRATORY DISEASE, FOWL CHOLERA AND NECROTIC E N T E R I T I S I N A V I A N SPECIES Guy T Carter, Michae Greenstein, Joseph J Goodman, Donald B Borders, William M Maiese, Raymond T Testa assigned to American Cyanamid Company This invention provides a method for treating chronic respiratory disease, fowl cholera and necrotic enteritis in infected birds, by orally administering thereto a pharmaceutically effective amount of antibiotic LL-E19020 alpha, antibiotic LL-E19020 beta or a physiologically acceptable salt thereof.
Masayasu Inoue, Tetsuya Ogino, Yoshimasa Morino, Masahiko Hirota, Kumamoto, Japan assigned to Inoue Masayasu; Kuraray Co Ltd Novel superoxide dismutase derivatives are provided in which the enzymatic activity of superoxide dismutase capable of decomposing superoxide, a substance harmful to living organisms, is for the most part maintained with the plasma half-life being significantly prolonged as compared with superoxide dismutase itself. They have pharmacological activities such as antiinflammatory, anti-ischemic and cerebral edema-preventing activities. Also provided are a method of producing such superoxide dismutase derivatives and medicinal uses of them.
4970070 4968603 DETERMINATION NEOPLASTIC
OF STATUS DISEASE
IN
PROTECTIVE MONOCLONAL ANTIBODY COMPOSITIONS FOR INFECTIONS DUE TO GROUP B STREPTOCOCCUS
Dennis J Slamon, William L McGuire assigned to The Regents of the University of California
Howard V Raft assigned to Genetic Systems Corporation
Amplification of the HER-2/neu oncogene is related to the status of neoplastic diseases, particularly breast and ovarian adenocarcinomas.
Immortalized cell lines have been produced that secrete human monoclonal antibodies capable of binding to bacterial species which are a major
123
PATENT ABSTRACTS cause of neonatal sepsis and meningitis. These antibodies have been found to be protective against lethal challenges of these bacteria, which include group B streptococcus, E. coli, KI, and Neisseria meningitidis group B. Pharmaceutical compositions containing these antibodies, which can be in combination with other monoclonal anitbodies, blood plasma fractions and antimicrobial agents, and the prophylactic and therapeutic use of such compositions in the management of infections, are included.
49701~ METHOD FOR INSERTING FOREIGN GENES INTO CELLS USING PULSED RADIOFREQUENCY Donald C Chang assigned to Baylor College of Medicine Disclosed are an apparatus and a method for the poration and fusion of cells using high-power radiofrequency electrical pulses. The electrodes of the apparatus can be hand held or part of integrated equipment with special containers for cells. The electrodes, which are positioned equidistant from each other, are attached to a high power function generator. The power function generator can apply a continuous AC electrical field and/or a high-power pulsed radiofrequency electrical field across the electrodes. The alternating electrical field induces cell congregation by the process of dielectrophoresis. The highpower pulsed radiofrequency electrical field porates or fuses the cells. The method has the ability to porate or fuse biological cells with a very high efficiency. The method can be used to fuse or porate a variety of cells including animal cells, human cells, plant cells, protoplasts, erythrocyte ghosts, liposomes, vesicles, bacteria and yeasts. The method has the unique ability to porate or fuse cells in very small or very large numbers. During the poration or fusions, a variety of chemical agents including DNA, RNA, antibodies, proteins, drugs, molecular probes, hormones, growth factors, enzymes, organic chemicals and inorganic chemicals can be introduced into these cells. The method can also be used to produce new biological species, to make hybridoma cells which produce animal or human monoclonal antibodies and to insert therapeutic genes into human cells which can be transplanted back into the human body to cure genetic diseases.
4970161 HUMAN
INTERFERON-GAMMA
Tetsu Kakutani, Keiji Matsumoto, Hiroyuki Maruyama, Kaku Nakagawa, Shinichi Yokota, Hideo Niwa, Katsuhiro Shinjo, Hajime Kawaharada, Kiyoshi Watanabe, Kakogawa, Japan assigned to Kanegafuchi Kagaku Kogyo Kabushiki Kaisha A DNA sequence on which a chromosomal DNA sequence coding for human interferongamma (HuIFN- gamma) and having a TATA box is ligated to a sequence of a promoter. Cell cultures transformed with said DNA revealed a higher expression of HuIFN- than cell cultures transformed with a DNA which does not have such TATA box. When transformed with said DNA, cell cultures produced HuIFN- gamma in a serum free medium. Transformed cell cultures derived from blood cells of HulFN- gamma resistant human cell-line also could produce HuIFN- gamma.
4970198 ANTITUMOR ANTIBIOTICS (LL-E33288 COMPLEX) May D Lee, Michael Greenstein, David P Labeda, Amedeo A Fantini assigned to American Cyanamid Company Antibacterial and antitumor agents designated LL-E33288 complex and their production by new strains of Micromonospora echinospora ssp. calichensis NNRL-15839, NRRL-15975 and NRRL-! 8149, are disclosed.
4970299 MONOCLONAL ANTIBODIES SELECTIVE FOR PROSTATE CANCER Miche Bazinet, Richard J Cote, Lloyd J Old assigned to Sloan-Kettering Institute for Cancer Research Four monoclonal antibodies are found which selectively identify prostate cancer. These monoclonals are therefore useful in diagnosis, differential diagnosis and treatment of prostate cancer.
PATENT ABSTRACTS
4966999 RADIOHALOGENATED COMPOUNDS FOR SITE SPECIFIC LABELING Daniel J Coughlin, Benjamin A Belinka, Vernon Alvarez assigned to Cytogen Corporation Radiohalogenated compounds which are useful as intermediates for preparing radiohalogenated antibody conjugates in which the radiohalogenated compound is site specifically attached to an oxidized carbohydrate moiety of an antibody or antibody fragment are disclosed. Methods for making the compounds and the antibody conjugates as well as methods of use of the same are also disclosed In particular, phenolic hydrazide and phenolic amine compounds are disclosed.
The presence of multiple gene copies in tumor cells indicates that the disease is more likely to spread beyond the primary tumor site, and that the disease therefore may require more aggressive treatment than might otherwise be indicated by other diagnostic factors. In particular, the degree of gene amplification appears to provide greater prognostic utility than either the estrogen receptor or the progesterone receptor, and provides utility equal to that of the determination of lymph node status. The information provided by the gene amplification test, however, is not duplicative with the determination of lymph node status and the two tests together provide greatly improved prognostic utility.
4968616 SUPEROXIDE DISMUTASE DERIVATIVES, METHOD OF PRODUCING SAME AND MEDICINAL USE OF SAME
4968493 METHOD FOR CONTROLLING CHRONIC RESPIRATORY DISEASE, FOWL CHOLERA AND NECROTIC E N T E R I T I S I N A V I A N SPECIES Guy T Carter, Michae Greenstein, Joseph J Goodman, Donald B Borders, William M Maiese, Raymond T Testa assigned to American Cyanamid Company This invention provides a method for treating chronic respiratory disease, fowl cholera and necrotic enteritis in infected birds, by orally administering thereto a pharmaceutically effective amount of antibiotic LL-E19020 alpha, antibiotic LL-E19020 beta or a physiologically acceptable salt thereof.
Masayasu Inoue, Tetsuya Ogino, Yoshimasa Morino, Masahiko Hirota, Kumamoto, Japan assigned to Inoue Masayasu; Kuraray Co Ltd Novel superoxide dismutase derivatives are provided in which the enzymatic activity of superoxide dismutase capable of decomposing superoxide, a substance harmful to living organisms, is for the most part maintained with the plasma half-life being significantly prolonged as compared with superoxide dismutase itself. They have pharmacological activities such as antiinflammatory, anti-ischemic and cerebral edema-preventing activities. Also provided are a method of producing such superoxide dismutase derivatives and medicinal uses of them.
4970070 4968603 DETERMINATION NEOPLASTIC
OF STATUS DISEASE
IN
PROTECTIVE MONOCLONAL ANTIBODY COMPOSITIONS FOR INFECTIONS DUE TO GROUP B STREPTOCOCCUS
Dennis J Slamon, William L McGuire assigned to The Regents of the University of California
Howard V Raft assigned to Genetic Systems Corporation
Amplification of the HER-2/neu oncogene is related to the status of neoplastic diseases, particularly breast and ovarian adenocarcinomas.
Immortalized cell lines have been produced that secrete human monoclonal antibodies capable of binding to bacterial species which are a major
123
PATENT ABSTRACTS cause of neonatal sepsis and meningitis. These antibodies have been found to be protective against lethal challenges of these bacteria, which include group B streptococcus, E. coli, KI, and Neisseria meningitidis group B. Pharmaceutical compositions containing these antibodies, which can be in combination with other monoclonal anitbodies, blood plasma fractions and antimicrobial agents, and the prophylactic and therapeutic use of such compositions in the management of infections, are included.
49701~ METHOD FOR INSERTING FOREIGN GENES INTO CELLS USING PULSED RADIOFREQUENCY Donald C Chang assigned to Baylor College of Medicine Disclosed are an apparatus and a method for the poration and fusion of cells using high-power radiofrequency electrical pulses. The electrodes of the apparatus can be hand held or part of integrated equipment with special containers for cells. The electrodes, which are positioned equidistant from each other, are attached to a high power function generator. The power function generator can apply a continuous AC electrical field and/or a high-power pulsed radiofrequency electrical field across the electrodes. The alternating electrical field induces cell congregation by the process of dielectrophoresis. The highpower pulsed radiofrequency electrical field porates or fuses the cells. The method has the ability to porate or fuse biological cells with a very high efficiency. The method can be used to fuse or porate a variety of cells including animal cells, human cells, plant cells, protoplasts, erythrocyte ghosts, liposomes, vesicles, bacteria and yeasts. The method has the unique ability to porate or fuse cells in very small or very large numbers. During the poration or fusions, a variety of chemical agents including DNA, RNA, antibodies, proteins, drugs, molecular probes, hormones, growth factors, enzymes, organic chemicals and inorganic chemicals can be introduced into these cells. The method can also be used to produce new biological species, to make hybridoma cells which produce animal or human monoclonal antibodies and to insert therapeutic genes into human cells which can be transplanted back into the human body to cure genetic diseases.
4970161 HUMAN
INTERFERON-GAMMA
Tetsu Kakutani, Keiji Matsumoto, Hiroyuki Maruyama, Kaku Nakagawa, Shinichi Yokota, Hideo Niwa, Katsuhiro Shinjo, Hajime Kawaharada, Kiyoshi Watanabe, Kakogawa, Japan assigned to Kanegafuchi Kagaku Kogyo Kabushiki Kaisha A DNA sequence on which a chromosomal DNA sequence coding for human interferongamma (HuIFN- gamma) and having a TATA box is ligated to a sequence of a promoter. Cell cultures transformed with said DNA revealed a higher expression of HuIFN- than cell cultures transformed with a DNA which does not have such TATA box. When transformed with said DNA, cell cultures produced HuIFN- gamma in a serum free medium. Transformed cell cultures derived from blood cells of HulFN- gamma resistant human cell-line also could produce HuIFN- gamma.
4970198 ANTITUMOR ANTIBIOTICS (LL-E33288 COMPLEX) May D Lee, Michael Greenstein, David P Labeda, Amedeo A Fantini assigned to American Cyanamid Company Antibacterial and antitumor agents designated LL-E33288 complex and their production by new strains of Micromonospora echinospora ssp. calichensis NNRL-15839, NRRL-15975 and NRRL-! 8149, are disclosed.
4970299 MONOCLONAL ANTIBODIES SELECTIVE FOR PROSTATE CANCER Miche Bazinet, Richard J Cote, Lloyd J Old assigned to Sloan-Kettering Institute for Cancer Research Four monoclonal antibodies are found which selectively identify prostate cancer. These monoclonals are therefore useful in diagnosis, differential diagnosis and treatment of prostate cancer.